These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18821278)

  • 41. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
    Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
    Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
    Gomez-Reino JJ; Carmona L;
    Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.
    Bullano MF; McNeeley BJ; Yu YF; Quimbo R; Burawski LP; Yu EB; Woolley JM
    Manag Care Interface; 2006 Sep; 19(9):47-53. PubMed ID: 17017313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of psoriatic arthritis therapies.
    Gladman DD
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
    Benucci M; Nenci G; Cappelletti C; Manfredi M
    Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis.
    D'Angelo S; Cutro MS; Lubrano E; Leccese P; Mennillo GA; Ferrara N; Olivieri I
    Ann Rheum Dis; 2010 May; 69(5):934-5. PubMed ID: 19666936
    [No Abstract]   [Full Text] [Related]  

  • 57. [Psoriasis updates].
    Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
    [No Abstract]   [Full Text] [Related]  

  • 58. Psoriatic arthritis.
    Gladman DD
    Dermatol Ther; 2004; 17(5):350-63. PubMed ID: 15379770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.
    Yamauchi PS; Mau N
    J Am Acad Dermatol; 2009 Jul; 61(1):158-60. PubMed ID: 19539861
    [No Abstract]   [Full Text] [Related]  

  • 60. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab.
    Puxeddu I; Giori L; Rocchi V; Bazzichi L; Bombardieri S; Tavoni A; Migliorini P; Del Corso I
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):123-4. PubMed ID: 22289732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.